Previously published ChIP-seq of wildtype ATF1 in the HepG2 hepatocellular carcinoma cell line identified 69.2% of 8863 ATF1 binding sites in promoters (Figure 3D) [45]. The gene discussed is ATF1; the disease is hepatocellular carcinoma.